Managers / Q3 2024 · view latest →
Propel Bio Management, LLC
CIK 0001969764 · 11620 WILSHIRE BLVD.,, SUITE 350, LOS ANGELES, CA, 90025 · 908-507-9629
Summary
Propel Bio Management, LLC reported $172M in U.S.-listed holdings across 21 positions for Q3 2024.
The portfolio is heavily concentrated: APLT alone accounts for 32.4% of reported value.
Compared with Q2 2024, the fund opened 3 new positions and exited 6.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 85.4% · $147M
- Ltd Part · 13.7% · $24M
- Other · 0.7% · $1M
- ADR · 0.3% · $504,000
Quarter-over-Quarter Changes full breakdown →
vs Q2 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ZVRAZEVRA THERAPEUTICS INC | NEW | +179.9K | 179.9K | +$1M | $1M |
| CMPSCOMPASS PATHWAYS LTD | NEW | +80.0K | 80.0K | +$504,000 | $504,000 |
| MAAT PHARMA SACA | NEW | +2.4K | 2.4K | +$17,786 | $17,786 |
| FULCFULCRUM THERAPEUTICS INC | SOLD OUT | −750.0K | 0 | −$5M | $0 |
| KYNKAYNE ANDERSON ENERGY INF | SOLD OUT | −147.0K | 0 | −$2M | $0 |
| TRVITREVI THERAPEUTICS INC | SOLD OUT | −260.0K | 0 | −$774,800 | $0 |
| FIDELITY INV MMTRSY 1 680 | SOLD OUT | −317.0K | 0 | −$317,014 | $0 |
| CYBIN INC | SOLD OUT | −850.0K | 0 | −$230,350 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2024
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $159M | 38 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $117M | 20 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $100M | 16 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 16 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $86M | 18 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $101M | 21 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $172M | 21 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $154M | 25 | Aug 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $172M | 29 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 34 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Simplify Asset Management Inc.028-20937
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.